We are building the iron products of the future
Bio Vitos combines deep scientific expertise with a proven ability to build and scale successful companies internationally. We are driven by the vision to eliminate the suffering caused by iron deficiency through side-effect-very-low treatments.
Our vision and strategy
Global leader in iron succinate therapies
Bio Vitos is a Swedish life science company in a transformative phase. By focusing on a unique, patented platform of iron succinate, we address unmet medical needs in heart failure and mental health. Our strategy is based on rapid clinical validation, regulatory approvals via EFSA and strong international expansion.
Board
Cato Crogh, CEO & Chairman
Cato Crogh is an entrepreneur and investor with over 30 years of experience scaling ventures across technology, digital platforms, and capital markets. Recently focused on AI and fintech, he drove the development of EQTOS AI and the expansion of Pepins.com and FundedByMe.com. Cato specializes in capital raising, international business, and M&A, with a core strength in building scalable business models that bridge advanced technology with commercial growth.
Andreas Stigas, Board Member
Andreas Stigas is an experienced entrepreneur and corporate leader within technology, finance, and digital business development. He has a proven track record of expanding companies across both private and public markets, working closely with investors and boards. Andreas specializes in corporate strategy, capital raising, international expansion, and strategic partnerships, bringing valuable competence to M&A transactions and shareholder value creation.
David Huseby, Board Member
David Huseby brings extensive leadership and corporate governance experience to Bio Vitos. He currently leads the strategic direction and active ownership at Venture Vault Capital and serves on the board of Letsfundly AB. Drawing from a solid background as a Chief Sales Officer (CSO), David specializes in commercial growth, high-level business development, and scaling operations within the venture ecosystem.
Management
Robert Simmons, Board Member & Marketing Manager
Background: 20+ years in life sciences, digital health and biotech.
Expertise: Has led investments totaling $235 million and completed nine successful exits.
Dr. Sven Rohmann, CMO
Background: MD, PhD and MBA with over 35 years of leadership experience in global bio-pharma.
Track record: Former CEO of Ganymed Pharmaceuticals AG, which was sold to Astellas for EUR 1.4 billion. Experience in leading successful clinical development programs and creating significant value for investors.
Scientific Advisor
Professor Fredrik Nyström
Professor of Internal Medicine and Endocrinology at Linköping University. Specialist in metabolic health with over 150 scientific publications. Leads the company’s clinical programs and regulatory studies.
Professor Hans Grönlund
Docent vid Karolinska Institutet and expert in immunology and biotech-innovation. Bidrar med djup kunskap inom antigensupptäckt och translationell forskning.
Our history
2010–2017
Founded in Sweden with a focus on medical technology and diagnostics to eliminate hemolysis.
2021–2023
Strategic restructuring towards drug development and acquisition of rights around ferrous succinate.
2024–2025
Intensification of clinical studies and preparations for international expansion.
2026
Focus on EFSA approval and planned listing on the US stock exchange.
Contact details
Head office: Artillerigatan 55, 114 45, Stockholm, Sweden
Email: [email protected]